Amgen buys back an osteoporosis drug from GSK; Regeneron launches a teaching fellowship;

@FierceBiotech: For those of you just waking up and getting to work in the U.S., here's our second issue of EuroBiotech: Read | Follow @FierceBiotech

@JohnCFierce: Amgen down 1.7%. I'm going to start calling Amgen a pharma co. If it walks like a duck... | Follow @JohnCFierce

@DamianFierce: Amgen: T-Vec hits on durable response but misses on OS, its secondary endpoint. Release | Follow @DamianFierce

@EmilyMFierce: The current environment for cancer care in Europe: Infographic via Janssen | Follow @EmilyMFierce

> AbbVie ($ABBV) gets out of the way as the EU prepares for trial transparency. More

> Amgen ($AMGN) is paying partner GlaxoSmithKline ($GSK) $275 million to get the sole rights to Prolia, a fast-selling osteoporosis drug. News

> According to a report commissioned by Johnson & Johnson ($JNJ), advances in cancer therapies have transformed certain tumor types from deadly ailments to, essentially, chronic diseases. More

> Regeneron ($REGN) has launched a teaching fellowship program through which high school STEM instructors will study alongside experts from the biotech and Columbia University. Item

Medical Device News

@FierceMedDev: J&J gets a mixed verdict in a trial alleging it sold faulty vaginal mesh implants. More | Follow @FierceMedDev

@MarkHFierce: ICYMI: Biotronik may have a relatively small U.S. mkt share, but it is working hard to compete here. Story | Follow @MarkHFierce

@MichaelGFierce: The year in nanotech drug delivery. Special report | Follow @MichaelGFierce

@EmilyWFierce: Adhesive medical sensors with origami-like wires could flex and bend with the skin, say researchers at Northwestern University. News | Follow @EmilyWFierce

> RefleXion raises $11.6M in Series A funding round. More

> Holaira brings in $42M Series D to test COPD lung denervation treatment tool. Article

> Vapotherm seals $24M financing round, elects new board member. Story

Pharma News

@FiercePharma: Trending on FierceVaccines: GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. More | Follow @FiercePharma

@TracyStaton: Still best-read FiercePharma: It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. Story | Follow @TracyStaton

@EricPFierce: RT: Last year, my sister died, and I learned first-hand about life sciences' limits. Article from FierceMedicalDevices | Follow @EricPFierce

@CarlyHFierce: Amgen, GSK part on fast-selling Prolia, mostly. More | Follow @CarlyHFierce

> Meda spurns Mylan takeover bid. News

> FDA's OK of opioid overdose treatment doesn't quell backlash over Zohydro. Article

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.